

ASX RELEASE (2 August 2024)

Epsilon Healthcare announces a new Pharmacy Vertical Integral

Epsilon Healthcare (**ASX: EPN**) (Epsilon or the Company), a leading company in Pharmaceutical Contract Development and Manufacturing & Telehealth operations, is pleased to announce the establishment of a new business vertical aimed at enhancing the Company's strategic growth and diversification efforts. This new vertical, **Epsilon Pharmacy**, represents a significant milestone in the Company's commitment to innovation and expansion within the health and wellbeing markets.

Highlights

- Epsilon Healthcare launches the Epsilon Pharmacy brand;
- Epsilon Pharmacy to provide Business to Consumer (B2C) dispensing and information services;
- New Pharmacy brand to sit as a subsidiary of Epsilon Healthcare and beside its other current and emerging subsidiary entities;
- Brand alignment which commenced in late 2023, to provide launching platform for new future subsidiary verticals

Overview of Epsilon Pharmacy

Epsilon Pharmacy will focus on the provision of pharmaceutical dispensing services and the provision of medication information as it seeks to promote the quality use of medicines. Leveraging industry expertise possessed by management & the team and a robust infrastructure, the pharmacy vertical seeks to build on Epsilon Healthcare's Business to Consumer offering and leverage emerging trends and market opportunities. By entering this space, the Company aims to broaden market reach and strengthen its competitive position in the industry.

The Epsilon Healthcare Group CEO & Managing Director, Peter Giannopoulos said "This initiative represents a strategic expansion into a high-growth market segment, providing our Company with the opportunity to diversify into a new segment, create new business opportunities and expand our customer base".

"Our new Epsilon Pharmacy brand is the newest addition to our new 'one brand' strategy which was launched in August 2023. We will be continuing to unite the distinct subsidiary brands under the umbrella of **Epsilon**. Our future subsidiaries will follow this naming convention and it is hoped that in time that our clients both B2B and B2C will benefit from the expanded Epsilon service verticals".



The new Board of Epsilon Healthcare is committed to sustainable long-term value creation and increased operational efficiency across all subsidiary operations through the generation of complimentary synergies.

The Board is pleased that the Company has come out of Administration on 24 June 2024 and is committed to the diversification of operations and service offerings, delivering innovation by fostering the development of new products and services which meet evolving client, patient and consumer needs.

The Epsilon Board is confident that this planned expansion through the Epsilon Pharmacy brand will contribute positively and reinforce our position as a leader in the specialised healthcare landscape.

Separately, the Board will address in future announcements those matters which arose and resulted in the suspension of the Company from Australian Securities Exchange including what steps are being taken to remediate. The Epsilon Board will transparently share with the market all material actions which are taken to address the circumstances which resulted in the Company being placed into Administration in December 2023.

The Announcement has been approved by the full Board of the Company

Alan Beasley
Chairman

ENDS

For further information, please contact:

Peter Giannopoulos
Group Chief Executive Officer & Managing Director
e: corporate@epsilonhc.com



Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare Limited (**ASX: EPN**) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacture & pharmacy dispensing and information services.

